Dr David M. Schuster, Senior Director of Research and Development,
Dave Schuster is a 35-year veteran of the life sciences industry and currently heads Research and Development for QIAGEN Beverly. He was a founding employee of Quanta Biosciences and as the Director of Research of Development was responsible for development of the Quantabio product portfolio since the Company’s inception in 2001. Quantabio was acquired by QIAGEN in 2011 and moved operations to QIAGEN Beverly (Beverly, MA) in 2016 to enhance their quality standards to ISO 13485.
Dave has a proven ability to develop custom reagent solutions for challenging problems and was instrumental in the conception and implementation of Quantabio’s custom development strategy through close scientific interactions with clients. He is a well-known expert in qPCR and related technologies and also brings a broad range of technical knowledge and experience in analytical methods in genomics, functional genomics and genetic analysis. Prior to Quantabio, Dave held a variety of R&D management positions at Life Technologies ( including Principal Scientist and Manager of R&D for the qPCR program. During his tenure at Life Technologies, he developed numerous products and technologies for RT-PCR, isothermal amplification and detection of nucleic acids, and in vitro transcription, including Invitrogen’s SuperScript® I/II, SuperScript RT-PCR Systems and Platinum® Taq. As Senior Scientist in the Molecular Diagnostic Division of Life Technologies he made significant contributions to the development of molecular diagnostic assays and technologies for detection of human papilloma viruses, cytomegalovirus, and hepatitis B.
David has a MS degree in Biomedical Sciences from Hood College and is author or coauthor of more than 20 scientific papers and multiple issued and pending patents.
Likely presentations include: